---
document_datetime: 2025-12-19 12:11:15
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/leflunomide-medac-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: leflunomide-medac-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.6617718
conversion_datetime: 2026-01-03 12:47:15.21108
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Leflunomide medac

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                        |
|----------------------|-------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------|
| Variation type IB /  | C.I.2 Change(s) in the Summary of Product | 19/12/2025                          |                                             | SmPC and PL                      | To update Sections 4.4 and 4.8 of the SmPC and |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000315571                     | Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.2.a (Type IB) - To update Sections 4.4 and 4.8 of the SmPC and Section 4 of the PL to implement the signal recommendations on pulmonary nodule (EPITT no 20155) following assessment of the same change for the reference product Arava (EMA/VR/0000279486). In addition, the MAH took the opportunity to update the contact details for the Local Representative   |            |     | Section 4 of the PL to implement the signal recommendations on pulmonary nodule (EPITT no 20155) following assessment of the same change for the reference product Arava (EMA/VR/0000279486).                                                                     |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000275636 | C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Other RMP changes (e.g. agreed wording + template change) - Accepted - - Accepted C.I.11.z (IB) - To update the RMP to adapt the list of safety concerns in line with approved changes to the RMP of the reference product Arava. Additionally, the                                                                                                                                                                                                                                                            | 04/07/2025 | N/A | To update the RMP to adapt the list of safety concerns in line with approved changes to the RMP of the reference product Arava. Additionally, the MAH took the opportunity to update the RMP in alignment with the GVP Module V revision 2 and to change the QPPV |

<div style=\"page-break-after: always\"></div>

|                                       | MAH took the opportunity to update the RMP in alignment with the GVP Module V revision 2 and to change the QPPV.                                                                                                                                                                                                                                                                                                                                                                                                                              |            |     |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IA / EMA/VR/0000272966 | This was an application for a group of variations. B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted B.II.d.2 Change in test procedure for the finished product - B.II.d.2.a Minor changes to an approved test procedure - Accepted B.II.d.2 Change in test procedure for the finished product - B.II.d.2.a Minor changes to an approved test procedure - Accepted | 21/05/2025 | N/A |